India's Piramal Pharma up after FDA closes inspection of US facility
** Shares of Piramal Pharma PIRM.NS rise as much as 4.2%
to 147.40 rupees, last up 2.1%
** Co says US FDA inspection of manufacturing facility at
Riverview, United States has been closed; establishment
inspection report issued
** PIRM on track for third straight session of gains
** Stock trading above its 50-, 100-, and 200-day moving
averages since early April
** About 2.3 mln shares change hands, half the 30-day avg
** Stock up ~4% YTD, had gained 24% in 2023
(Reporting by Dimpal Gulwani in Bengaluru)
((dimpal.gulwani@thomsonreuters.com))
Recent news on Piramal Pharma (Mumbai)
See all newsBrief: Piramal Pharma Receives Permanent Revocation Of Closure Order For Dahej Site
Brief: Piramal Pharma Solutions Announces Partnership With Botanix To Support Drug Substance Development
Brief: Piramal Pharma Announces Successful Closure Of Us FDA Inspection At Digwal Facility
India's Piramal Pharma eyes complex drug demand for earnings boost, chair says
Brief: Piramal Pharma Says Closure Of US FDA Inspection At Manufacturing Facility At Lexington